Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amphastar Pharma (NQ: AMPH )

50.73 +0.20 (+0.40%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharma

< Previous 1 2 3 4 5 6 7 Next >
Amphastar Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
Via ACCESSWIRE
Emergent BioSolutions Soars: Analyst Upgrades Stock With Near 100% Upside After FDA's Positive Move
Via Benzinga
BioMarin Pharmaceutical Stock Shows Rising Relative Strength
BioMarin Pharmaceutical stock had its Relative Strength Rating upgraded to 77 on Thursday, up from 70 a day earlier. 
Via Investor's Business Daily
Alkermes Stock Sees Rising Relative Strength Rating
The Relative Strength (RS) Rating for Alkermes stock climbed into a new percentile Tuesday, as it got a lift from 69 to 77. 
Via Investor's Business Daily
Exelixis Stock Shows Rising Relative Price Performance; Still Shy Of Key Benchmark
In a welcome move, Exelixis stock saw its Relative Strength Rating improve to 73 on Monday, up from 69 a day earlier. 
Via Investor's Business Daily
Why Shares of Amphastar Pharmaceuticals Rose Today
The company reported a record revenue year and increased EPS. 
Via The Motley Fool
Earnings Outlook For Amphastar Pharmaceuticals
Via Benzinga
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2022
Via ACCESSWIRE
BioMarin Pharmaceutical Stock Sees IBD RS Rating Improve To 74
A Relative Strength Rating upgrade for BioMarin Pharmaceutical shows improving technical performance. Will it continue? 
Via Investor's Business Daily
Exelixis Stock Generating Improved Relative Strength Rating
Exelixis stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 69 to 76. 
Via Investor's Business Daily
Vertex Pharmaceuticals Stock Gets Technical Rating Upgrade
Vertex Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 67 to 77. 
Via Investor's Business Daily
Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg
Via ACCESSWIRE
Kala Pharmaceuticals Stock Showing Rising Market Leadership; Earns 83 RS Rating
On Friday, Kala Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded to 83, up from 67 a day earlier. 
Via Investor's Business Daily
3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones dropping around 80 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. 
Via Benzinga
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2023
Via ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference
Via ACCESSWIRE
Can This Company's Positive Results For Psychedelic Combination Treatment Provide Hope For Alcohol And Cocaine Addiction Problems?
There is a high probability that you may know someone battling some form of addiction. Whether it’s a problem with opioids, alcohol, cocaine, or even using pain meds, an unchecked addiction can be... 
Via Benzinga
Amphastar Pharmaceuticals to Present at the 2022 Jefferies London Healthcare Conference
Via ACCESSWIRE
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 7, 2022
Via ACCESSWIRE
Intercept Pharmaceutical Stock Sees RS Rating Rise To 91
Intercept Pharmaceutical shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Recursion Pharma Stock Earns Relative Strength Rating Upgrade; Hits Key Benchmark
Recursion Pharma stock cleared a key performance benchmark Monday, with its Relative Strength Rating upgraded to 89 from 76 the day before. 
Via Investor's Business Daily
7 Safe Stocks to Rely on When the Market Swerves
As volatility and uncertainty continue, it remains a good time to add these seven safe stocks to your portfolio. 
Via InvestorPlace
Amphastar Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference
Via ACCESSWIRE
Amphastar Pharmaceuticals's Return on Invested Capital Overview
Pulled from Benzinga Pro data, Amphastar Pharmaceuticals (NASDAQ:AMPH) showed a loss in earnings since Q1, totaling $17.35 million. Sales, on the other hand, increased by 2.57% to $123.47 million... 
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Amphastar Pharmaceuticals Receives FDA Approval for Epinephrine Pre-Filled Syringes
Via ACCESSWIRE
Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review
The major indexes continued to advance, despite some key warnings. 
Via Investor's Business Daily
Amphastar Pharmaceuticals: Q2 Earnings Insights
  Amphastar Pharmaceuticals (NASDAQ:AMPH) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Amphastar, Syndax Top Second-Quarter Estimates, But Runaway Biotechs At A Standstill
Amphastar came in well above forecasts, while Syndax had fewer than expected losses. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.